Onco-immunology and gastrointestinal cancers

Speaker: Dirk Arnold

In an ESMO expert interview, D. Arnold elaborates the prognostic value of Immunoscore in stage I-III colon cancer and the results of phase II study of nivolumab in refractory anal cancer, as presented at ASCO 2016 Annual Meeting. He says that he will be surprised if checkpoint inhibitors don’t find place soon in therapeutic algorithm of gastrointestinal malignancies.

Discussion Points

  • Rationale for the study
  • Key study findings
  • Practice perspective

Abstract  3500: Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.                                             

Abstract  3503: NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA).